Sandberg Avery A
Department of DNA Diagnostics, St. Joseph's Hospital and Medical Center, Phoenix, Arizona 85013, USA.
Curr Opin Oncol. 2004 Jul;16(4):342-54. doi: 10.1097/01.cco.0000129678.72521.e5.
The burgeoning body of information on the genetic changes present in and underlying the development and biology of human cancers has carried implications regarding the possible genetic events that are responsible for not only the genesis of these cancers but also the hope of the cure for these cancers. Chondrosarcomas are a group of tumors that fall into this category. The purpose of this review is to summarize the genetic findings in these tumors.
The histopathologic variability of chondrosarcomas is reflected in the complexity and lack of specificity of their cytogenetic and molecular genetic findings, except for extraskeletal myxoid chondrosarcomas. These are characterized in the preponderant number of cases by a translocation, t(9;22)(q22;q12), and in a small number of cases by variant translocations t(9;17)(q22;q11) and t(9;15)(q22;q21). These translocations lead to the formation of abnormal fusion genes and gene products (proteins). In each of these translocations, the CHN gene is involved, resulting in the chimeric fusion genes EWS/CHN, RBP56/CHN, and TCF12/CHN, respectively. The specific translocations and their associated molecular genetic changes are diagnostic of extraskeletal myxoid chondrosarcomas. The abnormal proteins resulting from these fusion genes aberrantly affect gene transcription and cellular signaling pathways thought to be responsible for initiating sarcoma formation. In skeletal (central) chondrosarcomas of varying histopathologic types, the cytogenetic and molecular genetic findings are variable, complex, and apparently lacking in specificity. These changes may reflect a stepwise process (or processes) of oncogenesis involving an array of genes.
Although some cartilaginous tumors are characterized by specific or recurrent chromosome alterations and molecular genetic changes, much is yet to be learned about the nature and sequence of these genetics events and about their unique role in the stepwise process involved in the development and biology of each tumor type, both malignant and nonmalignant. Until such time, some of the genetic changes, particularly the presence of specific translocations, can be of definite diagnostic value.
关于人类癌症发生和生物学过程中存在的基因变化及其潜在机制的信息不断涌现,这不仅对这些癌症的发生原因,也对其治愈希望所涉及的可能基因事件具有重要意义。软骨肉瘤就是这类肿瘤中的一种。本综述旨在总结这些肿瘤的基因研究发现。
软骨肉瘤的组织病理学变异性反映在其细胞遗传学和分子遗传学发现的复杂性及缺乏特异性上,但骨外黏液样软骨肉瘤除外。在大多数病例中,骨外黏液样软骨肉瘤的特征是存在t(9;22)(q22;q12)易位,少数病例存在变异易位t(9;17)(q22;q11)和t(9;15)(q22;q21)。这些易位导致异常融合基因和基因产物(蛋白质)的形成。在每种易位中,均涉及CHN基因,分别产生嵌合融合基因EWS/CHN、RBP56/CHN和TCF12/CHN。特定的易位及其相关的分子遗传学变化是骨外黏液样软骨肉瘤的诊断依据。这些融合基因产生的异常蛋白质会异常影响基因转录和细胞信号通路,而这些通路被认为是引发肉瘤形成的原因。在不同组织病理学类型的骨(中央)软骨肉瘤中,细胞遗传学和分子遗传学发现各不相同、复杂且明显缺乏特异性。这些变化可能反映了涉及一系列基因的肿瘤发生的逐步过程。
尽管一些软骨肿瘤具有特定的或反复出现的染色体改变和分子遗传学变化,但关于这些基因事件的性质和顺序,以及它们在每种肿瘤类型(包括恶性和非恶性)发生和生物学过程的逐步过程中所起的独特作用,仍有许多有待了解。在此之前,一些基因变化,特别是特定易位的存在,可能具有明确的诊断价值。